Teva and Sanofi Present New Positive Phase 2b Study Results at ECCO 2025 ReinforcingBest-in-Class Potential of Duvakitug (Anti-TL1A) in Ulcerative Colitis and Crohns Disease
Teva hosting investor call Monday, February 24 at 8:00 a.m. U.S. ET…
Teva to Host Conference Call on February 24, 2025 to Discuss New Data Presented for Duvakitug (anti-TL1A) Positive Phase 2b results at the 20th Annual Congress of the European Crohn’s and Colitis Organisation (ECCO)
February 18, 2025 16:30 ET | Source: Teva Pharmaceutical Industries Ltd TEL…
TAHO Pharmaceuticals Reports Positive Results from Pivotal Study of TAH3311, the First Oral Dissolving Film Anticoagulant
TAIPEI, Feb. 17, 2025 /PRNewswire/ -- TAHO Pharmaceuticals announces positive preliminary results…
EYLEA HD (aflibercept) Injection 8 mg Positive Phase 3 Results in Patients with Macular Edema following Retinal Vein Occlusion Presented at Angiogenesis Meeting
EYLEA HD led to improved vision with extended dosing intervals, achieving non-inferior…
4DMT Presents Positive 52-Week Results from Phase 2b Cohort of PRISM Wet AMD Study and Long-term Durability Data Supporting 4D-150 4FRONT Global Registration Program
February 08, 2025 14:30 ET | Source: 4D Molecular Therapeutics, Inc. 3E10…
The Largest Insurance Provider in Massachusetts Publishes Positive Reimbursement Policy for the Nerivio REN Wearable for Acute and Preventive Treatment of Migraine
BRIDGEWATER, N.J. and NETANYA, Israel, Feb. 05, 2025 (GLOBE NEWSWIRE) -- Theranica,…
Valneva Reports Positive Phase 2 Results in Children for its Chikungunya Vaccine and Announces Phase 3 Dose Decision
Saint-Herblain (France), January 22, 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris:…
Santhera Receives Positive Recommendation from Scottish Medicines Consortium for the Use of AGAMREE (Vamorolone) in Duchenne Muscular Dystrophy Patients in NHS Scotland
Santhera Receives Positive Recommendation from Scottish Medicines Consortium for the Use of…
PolyPid Announces Positive Recommendation by DSMB to Continue Enrollment of Phase 3 SHIELD II Trial of D-PLEX to 800 Patients with a Concurrent Private Placement of up to $41 Million
December 23, 2024 19:22 ET | Source: PolyPid Ltd. • 630 Patients…
Menarini Group announces Positive Topline Data from Pivotal Phase 3 BROADWAY & TANDEM Clinical Trials Evaluating Obicetrapib and the Fixed-Dose Combination Obicetrapib with Ezetimibe 10 mg
– Both pivotal studies achieved primary endpoints of LS mean reduction in LDL-C…